Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.

Shanghai Stock Exchange 600613.SS

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Revenue Per Share for the year ending December 31, 2023: USD 0.64

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Revenue Per Share is USD 0.64 for the year ending December 31, 2023, a -1.82% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Revenue Per Share for the year ending December 31, 2022 was USD 0.65, a -4.50% change year over year.
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Revenue Per Share for the year ending December 31, 2021 was USD 0.68, a 29.83% change year over year.
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Revenue Per Share for the year ending December 31, 2020 was USD 0.52, a -0.89% change year over year.
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. Revenue Per Share for the year ending December 31, 2019 was USD 0.53, a 3.84% change year over year.

Key data

Date	Revenue Per Share	Dividend Per Share	Free Cash Flow Per Share	Return on Assets (ROA)

Shanghai Stock Exchange: 600613.SS

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.

CEO	Mr. Feng Bin
IPO Date	Aug. 20, 1992
Location	China
Headquarters	Changfa Tower
Employees	1,426
Sector	Health Care
Industries Pharmaceuticals

Description

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, tonic products, cold and cough, children's medicine, and anti-fungal drugs. Its products include prescription drugs and OTC products. The company was founded in 1992 and is based in Shanghai, China.

Key trends

Past 5 years